Table 1.
Characteristics of the overall cohort
| n = 85 | |
|---|---|
| Age, years | |
| Median | 59.0 |
| Range | 26–83 |
| Gender, N (%) | |
| Male | 42 (49.4) |
| Female | 43 (50.6) |
| AJCC Stage, N (%) | |
| IV | 85 (100) |
| Liver metastasis, N (%) | |
| Synchronous | 85 (100) |
| First‐line chemotherapy, N (%) | |
| FOLFOX | 57 (67.1) |
| FOLFIRI | 18 (21.2) |
| Other | 10 (11.8) |
| First‐line antibody, N (%) | |
| Bevacizumab | 39 (45.9) |
| Cetuximab | 21 (24.7) |
| KRAS status, N (%) | |
| Mutant | 21 (24.7) |
| Wild‐type | 50 (58.8) |
| Unknown | 14 (16.5) |
| Primary tumour sidedness, N (%) | |
| Left | 54 (63.5) |
| Right | 31 (36.5) |
| Abdominal body composition, median (range), L | |
| Muscle | 5.77 (3.21–10.10) |
| Bone | 2.43 (1.66–3.84) |
| TAT | 10.57 (1.22–33.09) |
| SAT | 7.08 (0.50–21.33) |
| VAT | 2.59 (0.25–10.60) |
| IMAT | 0.89 (0.24–3.73) |
| Median survival time, months (95% CI) | 21.2 (15.6–27.2) |
| 1 year mortality rate, % (95% CI) | 23.5 (15.9–34.1) |
| Censored, N (%) | 6 (7.1) |